Strategic Partnerships Across Asia-Pacific Medical Device Regulation

Why Asia-Pacific Specifically

For foreign medical device manufacturers, "Asia-Pacific" is one of the most heterogeneous regulatory regions in the world. Japan's PMDA, China's NMPA, Korea's MFDS, Taiwan's TFDA, Singapore's HSA, Australia's TGA, Vietnam's DAV, Indonesia's BPOM, Thailand's TFDA — each operates differently, with different submission formats, different timelines, different audit expectations, and different language requirements.

A common pattern: a Western manufacturer entering Asia decides Japan first (large market, strong reputation), then Korea (smaller but mature), then maybe China (large but complex), then opportunistically into Southeast Asia. By the time the manufacturer has run four or five Asian submissions, they have engaged four or five different regulatory consulting firms because no single firm covered the depth they needed across markets.

The accumulated cost — across consultant fees, internal coordination, repeated technical file rebuilds — is substantial. The fragmentation is structural.

Our response is to do what we are competent to do directly (Korea, and increasingly the broader regional architecture) and to partner where partnership produces better outcomes than internal expansion would.

Where Leanabl Is the Practitioner

Korea is our home market. The senior team is Korean by experience and language. We are the practicing firm for:

• MFDS submissions (Class I, II, III, IV)
• KGMP certification and surveillance audits
• Korea License Holder (KLH) operations
• HIRA/NECA reimbursement pathways
• Korean post-market surveillance and vigilance
• Korean labeling and IFU development
• Korean distributor transitions

Within Korea, we operate as a full-service practice with our own staff. Clients do not interact with subcontractors for the Korean work; the team that proposes is the team that delivers.

Where We Operate Through Partners

For the rest of Asia-Pacific, we coordinate through specialist partner firms:

Japan (PMDA)

Japanese regulatory work — PMDA submissions, JPAL compliance, Japanese-language QMS — runs through Japanese partner firms with PMDA-side experience. The Japanese market has specific cultural and regulatory characteristics that benefit from native Japanese practitioners with PMDA pre-submission meeting experience.

Our role on Japan-inclusive engagements: program coordination, shared technical file architecture, ensuring the Japanese work integrates with parallel Korean (or other) workstreams.

China (NMPA)

China presents particular challenges — Chinese-language requirements throughout, a complex registration pathway with type testing, clinical evaluation expectations specific to China, and a regulator (NMPA) whose practices have evolved rapidly in the past five years. We work with NMPA specialists for this work.

The Chinese partner relationships are particularly carefully selected because the rate of practitioner quality variability in the Chinese consulting market is high.

Taiwan (TFDA)

Taiwan medical device regulation has its own framework, often (but not always) aligned with other regional approaches. We coordinate through Taiwanese partners with TFDA practice experience.

Southeast Asia (Vietnam, Thailand, Indonesia, Malaysia, Philippines, Singapore)

Each Southeast Asian market has distinct registration requirements. Singapore (HSA) has the most internationally aligned framework; Vietnam and Indonesia have the most country-specific. We coordinate per-country with Southeast Asian regional specialists.

The Southeast Asian regulatory landscape is changing as the ASEAN Medical Device Directive (AMDD) framework matures. Some convergence is expected over the coming years.

Australia and New Zealand (TGA, Medsafe)

Australia's TGA and New Zealand's Medsafe operate under frameworks that align more closely with EU MDR than with other Asian regulators. For Australia-inclusive engagements, we partner with TGA specialists.

The Cross-Region Coordination Model

For clients entering multiple Asia-Pacific markets, the coordination model:

1. Strategy phase — we set the regional sequencing, market prioritization, and shared technical file architecture. This phase typically involves senior practitioners from Leanabl and the relevant regional partners.

2. Execution phase — region-specific submissions run through the regional partners with shared technical content from a master file. Leanabl holds the central program management and Korean workstream.

3. Post-approval phase — region-specific post-market operations, with Leanabl coordinating where post-market activities cross regions (e.g., a vigilance event in one region that affects labeling in others).

The client experience is one project plan, one shared technical file, regular cross-region status reporting, and direct access to regional teams when the work requires it.

Why Not Build Asian Offices Ourselves

A frequent question from clients: why not expand to Tokyo, Shanghai, Singapore, etc., and bring everything in-house?

Three honest reasons:

1. Depth requires time. Senior PMDA practitioners are built over decades, not hired in a recruiting cycle. A new Tokyo office staffed with junior team members would not produce the quality our clients expect. We would rather partner with established Japanese firms than dilute the work.

2. The economics do not require it. Our partnership model produces good client outcomes at a reasonable cost. Building offices would add overhead without proportionate increase in quality or capacity.

3. The cultural fit varies. Regulatory consulting culture differs significantly across countries. The collaborative, transparent model that works in Korea may not be the right cultural choice for Japan or China. Letting regional teams operate within their own cultural frameworks — while coordinating to deliver one program to the client — produces better results than imposing a single culture.

We may revisit this in the future as the firm scales. For now, the partnership model is the deliberate choice.

The Trust Stack

Partnership-based service delivery depends on trust at multiple levels:

• Client trusts Leanabl to coordinate the program and to honestly recommend partner firms
• Leanabl trusts the partner firms to deliver quality region-specific work
• Partner firms trust Leanabl to manage the program fairly (the partner is not commoditized; the relationship is collaborative)

Trust at this depth takes years to build. Our oldest partner relationships date to before Leanabl existed as a firm — they are relationships between senior practitioners that long predate the corporate entities.

For clients, the practical implication is that the partner network is not a marketing structure. It is a working relationship that has been tested across many engagements. New partners are added carefully and infrequently.

What This Means for Korea-Focused Clients

For clients whose primary need is Korean regulatory work, the Asia-Pacific partner network is largely irrelevant. The Korean work runs entirely within Leanabl. The partners come into play only when the client expands beyond Korea.

For clients running parallel Asian submissions, the network matters significantly. The ability to coordinate Korean, Japanese, and Chinese workstreams without staffing three separate engagements is the operational benefit.

Where Leanabl Plugs In

For multi-region engagements that include Korea plus other Asia-Pacific markets, the Submissions service runs the program coordination with regional partners. The Partners page describes the partner network model in more detail, and Global Presence covers our regional reach. For Korea-only work, the solutions catalog has the full Korean offering.